Category: Novartis

Only 19% to 26% of patients with chronic myeloid leukemia (CML) discuss treatment decisions with their physician, a survey by Swiss-based pharmaceutical Novartis has revealed. The Survey of Unmet Needs in CML (CML SUN), which investigated how patients and physicians felt about current treatment options, joint decision-making, and treatment satisfaction,…

Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China Experienced a Venous Thromboembolism within the First 6 Months of Diagnosis Abelacimab is Already Being Studied in 23 Countries throughout North…

PRESS RELEASE Published June 8, 2023 Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. Today, biotechnology is being used to create new and improved crop varieties, develop renewable fuels, and create new industrial and consumer products….

Funding Support and Acknowledgements: COPDGene: The project described was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung,…

A chronic inflammatory condition known as non-radiographic axial spondyloarthritis (axSpA) remained undetectable on X-ray for most people with active disease who were on treatment with Cosentyx (secukinumab) for up to two years. That’s according to new data from PREVENT (NCT02696031), a Phase 3 clinical study that also showed sustained reduction in…

NEW YORK, N.Y. — June 2. Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.  Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis)…

MT Newswires 2023 All news about NOVARTIS AG Analyst Recommendations on NOVARTIS AG Sales 2023 53 259 M – – Net income 2023 9 819 M – – Net Debt 2023 8 051 M – – P/E ratio 2023 20,5x Yield 2023 3,67% Capitalization 206 B 207 B – EV / Sales 2023 4,02x…

By Giulia Petroni Novartis said that primary endpoint data from a Phase 3 trial showed that ribociclib drug treatment Kisqali significantly reduced the risk of cancer recurrence across a broad population of patients with early breast cancer. The Swiss pharma giant on Friday said that ribociclib combined with endocrine therapy…

NEW YORK, June 2, 2023 /PRNewswire/ — Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation…

MANNHEIM, Germany — A novel drug that targets production of a liver protein involved in lipid metabolism appears to markedly reduce low-density lipoprotein (LDL) cholesterol levels for patients with homozygous familial hypercholesterolemia (HoFH), suggest results from the phase 2 GATEWAY trial. The research was presented at the European Atherosclerosis Society…

Over the past decade, a large portion of the resources dedicated to scientific research has been focused on solving widespread unmet medical needs. This is particularly true within cancer, where many patients have limited treatment options. One of the most promising treatment approaches, which is equally as complex as cancer,…

Dave Morgenstern, PhD DELFI Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Dave Morgenstern, PhD, as Vice President of Clinical Development. Dave joins DELFI from Roche Diagnostics, where he spent more than a decade in clinical development…

  “Coherent Market Insights offers a 25% discount on Pharmacogenomics Market Reports on Single User Access and Unlimited User Access” Pharmacogenomics Market Size Projections : Global pharmacogenomics market is estimated to be valued at US$ 14,028.01 million in 2022 and is expected to exhibit a CAGR of 11.1% during the forecast period (2023-2030). Pharmacogenomics, often known as pharmacogenetics, is a branch…

It was 2013 when the first anti-meningococcus B vaccine was authorized by the European Medicines Agency Ema, and shortly after by the Italian Aifa. A goal that in the early 90s was considered an “impossible” mission. Scientist Rino Rappuoli, the father of ‘reverse vaccinilogy’, the technique that allowed the development…

Intellia Therapeutics, Inc., a clinical stage genome editing company, has seen a significant decrease in its short interest during the month of May. The short interest totalled 5,940,000 shares as of May 15th. This is a decrease of approximately 13% from the April 30th total of 6,830,000 shares. With an…

Data Bridge Market Research announces the release of the report “Mild Cognitive Impairment (MCI) Treatment Market Size, Share, Growth & Trends Analysis Report By Product, By End Use, By Region And Segment Forecasts”. An excellent Mild Cognitive Impairment (MCI) Treatment market document concentrates on the global key manufacturers to define,…

By Sharvari Rale, Fairfield Market Research The quest for the most effective disease treatments has become more urgent than ever. The global chronic disease burden is swelling at alarming rates, pointing to growing severity of the situation for the global healthcare system, economy, and public health. Prevalence of chronic conditions…

Relapsed or Refractory Diffuse Large B-cell Lymphoma Market The relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1,364 million in 2022 and is expected to exhibit a CAGR of 4.2% over the forecast period (2023-2030).” — Coherent Market Insights SEATTLE, WASHINGTON, INDIA, May…

byakkaya Cogent Biosciences (NASDAQ:COGT) offers a compelling investment opportunity for those seeking exposure to a pioneering biotech company revolutionizing the development of precise therapies for genetically influenced diseases. By focusing on targeted treatments such as bezuclastinib and investigating novel ErbB2 and FGFR2 inhibitors, Cogent Biosciences showcases enormous potential in addressing…

The Gist Data insight. IoT informs product enhancements. Customer experience. Real-time data optimizes CX. Business models. IoT refines equitable billing. In the era of the Internet of Things (IoT), “smart,” interconnected devices are generating invaluable data for businesses. This data-driven approach is empowering these businesses to make informed decisions, enhancing their products…

AVROBIO, Inc., a clinical-stage gene therapy company working to free people from a lifetime of genetic disease, has agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash.  AVROBIO retains full rights to its portfolio of…

In an uncertain economic environment, biotechnology stocks have been outpacing the overall stock market. However, Morningstar analysts say there are still undervalued stocks in this innovative industry. Among the biotech stocks trading at attractive prices are prominent names such as Moderna MRNA, which was in the spotlight for its COVID-19…

(MENAFN– EIN Presswire) Molecular Diagnostics Market Growth Increase in the prevalence of infectious diseases and various types of cancer drives the growth of the molecular diagnostics market. PORTLAND, OREGON, UNITED STATES, May 24, 2023 /einpresswire.com / — Allied Market Research published a report, titled, “molecular diagnostics market by Type (Instruments,…

AbbVie (ABBV Quick QuoteABBV – Free Report) and partner Genmab (GMAB Quick QuoteGMAB – Free Report) announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The new drug will be marketed by the trade name of…

AbbVie ABBV and partner Genmab GMAB announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The new drug will be marketed by the trade name of Epkinly.  Continued approval for this indication will be based on data…

Global Biotechnology Market Size & Share to Surpass $2772.7 Billion by 2030 | Vantage Market Research WASHINGTON, May 22, 2023 (GLOBE NEWSWIRE) — The Global Biotechnology Market is valued at USD 1094.6 Billion in 2022 and is projected to reach a value of USD 2772.7 Billion by 2030 at a…

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy….

– Continued Treatment with Patisiran in Open-Label Extension Period Showed Evidence of Sustained Benefit across Measures of Functional Capacity and Health Status and Quality of Life, as well as Cardiac Stress and Injury, through 18 Months – – Safety Profile Consistent with that Observed in 12-Month Double-Blind Period, with No…

– Continued Treatment with Patisiran in Open-Label Extension Period Showed Evidence of Sustained Benefit across Measures of Functional Capacity and Health Status and Quality of Life, as well as Cardiac Stress and Injury, through 18 Months – – Safety Profile Consistent with that Observed in 12-Month Double-Blind Period, with No…

mi-viri Key competitor update & our take: Sparsentan falters as expected On May 1st, Travere Therapeutics (TVTX) announced disappointing data from their DUPLEX Phase 3 study focusing on FSGS. The study did not achieve the primary efficacy endpoint for eGFR slope over a 108-week treatment period in a statistically significant…

PRESS RELEASE Published May 19, 2023 The global progressive familial intrahepatic cholestasis type 2 treatment market size was valued at USD 35 million in 2021 and is projected to reach around USD 550 million in 2030 exhibiting a CAGR of 39.0% in the forecasted period.  Introduction The Global Progressive Familial…

Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Owing to the high success rate during the preclinical and clinical trials, cancer gene therapy has gained popularity. There are many techniques used for…

Diffuse large B-cell lymphoma (DLBCL) made headlines earlier this year with the high-profile case of prominent U.S. Congressman Jamie Raskin (D-MD). Yet, until very recently, progress in treating this most common form of lymphoma has been stalled for more than 2 decades. Significant breakthroughs have come in just the past…

On May 17, 2023, AstraZeneca announced positive findings from the Phase 3 FLAURA2 trial of Tagrisso (osimertinib) combined with chemotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor mutations. The study demonstrated that Tagrisso and chemotherapy together resulted in a significant improvement in…

News Home Tuesday, May 16, 2023 12:47 PM | InvestorsObserver Analysts Mentioned in this article The market has been high on Intellia Therapeutics Inc (NTLA) stock recently. NTLA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Intellia Therapeutics Inc has a Bullish sentiment reading. Find out what this means…

PRESS RELEASE Published May 17, 2023 DelveInsight’s, “CRISPR Therapies Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including CRISPR Therapies clinical trials and nonclinical stage products. It also covers the therapeutics…

Job Description799 million. That’s how many lives our products touched in 2019. The Principal RWE Research Analyst, Bioinformatics is responsible for the scientific and methodological aspects of all Real World Evidence projects as well as providing guidance for other members of the team. In this role, we are looking for…

High Potency Active Pharmaceutical Ingredients Market The global High Potency Active Pharmaceutical Ingredients market size is expected to reach USD 40.99 billion by 2030, registering a CAGR of 9.9% from 2023 to 2030, according to a new report by Coherent Market Insight Inc. High potency active pharmaceutical ingredients (HPAPIs) encompass…

PRESS RELEASE Published May 12, 2023 (New York, USA) DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma (DLBCL) market trends in the United…

PRESS RELEASE Published May 11, 2023 The global relapsed or refractory diffuse large B-cell lymphoma market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.2% in the forecasted period. The market demand is being…

PRESS RELEASE Published May 11, 2023 Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. Today, biotechnology is being used to create new and improved crop varieties, develop renewable fuels, and create new industrial and consumer products….

PRESS RELEASE Published May 10, 2023 Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America,…

May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million “In the first quarter of the year we continued to lay the groundwork for the potential approval of epcoritamab…

PRESS RELEASE Published May 10, 2023 “Diffuse Large B-cell Lymphoma (DLBCL) Market” (New York, USA) DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma…

Diffuse Large B-cell Lymphoma (DLBCL) Market (New York, USA) DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma (DLBCL) market trends in the United…

CRISPR Therapeutics AG (NASDAQ:CRSP) has been making headlines recently with its innovative gene-editing technology. The company has received a consensus rating of “Hold” from the twenty-one brokerages that are presently covering the company, according to Bloomberg Ratings reports. However, despite this rating, CRISPR Therapeutics has seen two investment analysts rate…

According to HTF Market Intelligence, the Global Nucleic Acid Testing market to witness a CAGR of 8.4% during forecast period of 2023-2028. The market is segmented by Nucleic Acid Testing Comprehensive Study by Type (Nucleic Acid Test Kits, Consumables), Nucleic Acid Test Kits (Ligase Chain Reaction (LCR), Transcription–mediated Amplification (TMA),…

PRESS RELEASE Published May 5, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in the Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor…

Yahoo Finance published this video item, entitled “Why the human genome could be health care’s holy grail” – below is their description. #youtube #stockmarket #genetics 23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the…

Forward-looking Information This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be…

School: Biological Sciences / School of Sciences Position: Faculty Positions in Artificial Intelligence for Biomedicine Location: Suzhou, China Contract Type: Fixed-term, renewable. 3rd contract is open-ended ABOUT XJTLU In 2006 Xi’an Jiaotong-Liverpool University (XJTLU) was created by the University of Liverpool and Xi’an Jiaotong University – a top ten university in China. Offering a…

School: Biological Sciences / School of Sciences Position: Faculty Positions in Cell Biology Location: Suzhou, China Contract Type: Fixed-term, renewable. 3rd contract is open-ended ABOUT XJTLU In 2006 Xi’an Jiaotong-Liverpool University (XJTLU) was created by the University of Liverpool and Xi’an Jiaotong University – a top ten university in China. Offering a unique international…

CD19-directed CAR T-cell therapy Breyanzi has been approved by the European Commission (EC) based on significant results from a lymphoma Phase III trial. The European Commission (EC) has granted approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The CAR T-cell therapy has a 4-1BB…

COVINA, Calif., May 3, 2023 /PRNewswire/ — According to Prophecy Market Insights “Cell and Gene Therapy Market accounted for US$ 13.0 billion in 2022 and is estimated to be US$ 62.5 billion by 2032 and is anticipated to register a CAGR of 22.8%.” What is the Overview of Cell and Gene Therapy…

Reports And Data The aquaculture vaccines market was USD 3.76 Billion in 2022 and is expected to register a rapid revenue CAGR of 8.40% during the forecast period The aquaculture vaccines market was USD 3.76 Billion in 2022 and is expected to register a rapid revenue CAGR of 8.40% during…

Are you interested in pursuing a career in the rapidly expanding field of bioinformatics? If so, a Bachelor of Technology in Bioinformatics might be the perfect degree program for you. This interdisciplinary field combines computer science, biology, and mathematics to analyze biological data and solve complex problems related to genetics,…

Aditum Bio has announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders. Aditum Bio is a biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former president of the Novartis Institutes for BioMedical Research (NIBR) Mark…

Oculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued expansion following OCS listing into NASDAQ Oculis’s finance and development team strengthened by US-based hires, including Dr. Fang Li as Senior Vice President, Regulatory Affairs, who successfully led important FDA new…

PRESS RELEASE Published April 25, 2023 DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diffuse Large B-cell Lymphoma. DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diffuse Large B-cell Lymphoma,…

Fairchild, Lauren, Whalen, Jeanne, D’Aco, Katie, Wu, Jincheng, Gustafson, Ben, Su, Fei, Leary, Rebecca, Campbell, Katie and Balbin, Oscar (2023) Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. Science translational medicine, 15 (689). ISSN 1946-6242 Abstract In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP)…

PRESS RELEASE Published April 24, 2023 DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including Diffuse Large B-Cell Lymphoma clinical trials…

PRESS RELEASE Published April 24, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Sickle Cell Disease pipeline constitutes 40+ key companies continuously working towards developing 50+ Sickle Cell Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. “Sickle…

Novartis AG (NYSE: NVS) announced new long-term data from the ALITHIOS open-label extension study of Kesimpta (ofatumumab) for relapsing multiple sclerosis patients. Data showed that up to five years, patients treated earlier and continuously with Kesimpta (ofatumumab) had fewer disability worsening events and low brain volume change versus those who started on teriflunomide…

PRESS RELEASE Published April 18, 2023 The global Cellular and Gene Therapy Product market research report published by market insight reports discovers the current outlook in global and key regions from the viewpoint of Major Players, Countries, Product Types, and end industries. This report studies top players in the global…

Patients with unresectable metastatic desmoplastic melanoma, a rare amelonotic subtype of cutaneous melanoma, achieved high response rates when treated with single-agent pembrolizumab (Keytruda) in the SWOG S1512 trial (NCT02775851), according to data presented during the 2023 AACR Annual Meeting.1 “Based on these data, single-agent, anti-PD1 immunotherapy should be considered the…

PRESS RELEASE Published April 17, 2023 DelveInsight’s, “CAR-T Pipeline Insights 2023” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route…

VIDEO OF RESEARCHER AND PATIENT COMMENTARY IS AVAILABLE AT: bcove.video/3mxxASq   The combination of an experimental mRNA vaccine with an immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared to immunotherapy alone, a new clinical trial shows. Led by researchers at NYU Langone Health and…

CEL-SCI’s revolutionary advances are impressive; their data shows that overall survival increased by almost 4 years, and some tumors even dissipated after a mere three weeks of Multikine therapy. The passionate group at CEL-SCI is completing the necessary confirmations for their manufacturing plant with efficiency while collaborating closely with the…

NEW YORK, April 13, 2023 /PRNewswire/ — The CRISPR technology market size is forecasted to increase by USD 2.88 billion from 2021 to 2026, at a CAGR of 19.34%, according to a recent market study by Technavio. The growth of the market will be driven by the increasing demand for the…

Lives are saved when time from vein to vein decreases. Therapeutic biologics are thriving, according to Zhou Jiang, director Cell Culture Services at Cytiva. “As we work to advance the next generation of therapeutics, we must address these challenges to deliver the medicines patients need. The increasing diversity introduces new…

PRESS RELEASE Published April 12, 2023 DelveInsight’s, “CRISPR Therapies Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including CRISPR Therapies clinical trials and nonclinical stage products. It also covers the therapeutics…

PRESS RELEASE Published April 10, 2023 The global relapsed or refractory diffuse large B-cell lymphoma market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.2% in the forecasted period. The rise in the number…

PRESS RELEASE Published April 11, 2023 The biotechnology market is a rapidly growing industry that combines biology, chemistry, and engineering to develop innovative products and services for a range of applications in healthcare, agriculture, food production, and the environment. Here are some key points about the biotechnology market: Key players:…

Celltrion Healthcare shared preliminary data from a phase 3 clinical trial demonstrating that its omalizumab biosimilar (CT-P39) is comparable in safety and efficacy to the reference product (Xolair) in patients with chronic spontaneous urticaria, according to a report from the Korea Herald. Xolair (Genentech and Novartis) is used to treat…

SAN FRANCISCO , April 6, 2023 /PRNewswire/ — Mekonos announced today that Dr. Anil Narasimha, CEO & Co-Founder, will present at the annual Cell & Gene Meeting on the Med to be held April 12-14 in Barcelona, Spain and livestreamed globally. Mekonos is a cell & gene therapy platform company…

Marché du traitement du lymphome non hodgkinien à cellules B, marché du traitement du lymphome non hodgkinien à cellules B 2028, industrie du traitement du lymphome non hodgkinien à cellules B, secteur du traitement du lymphome non hodgkinien à cellules B, traitement du lymphome non hodgkinien à cellules B PDF…

Report Description: Coherent Market Insight has released a new research study titled “Graft Versus Host Disease (GvHD) Market” 2023 analysis by the following subjects: “Industry size, share, growth, segmentation, manufacturers and developments, key trends, market drivers, restraints, regulations, distribution methods, opportunities, strategies, potential road maps, and annual forecast until 2030′′….

Background Cell-free DNA (cfDNA) refers to fragments of DNA released into the circulation by endothelial cells and white blood cells by active release or passively through apoptosis and necrosis.1,2 The fraction of cfDNA that originates from tumor is known as circulating tumor DNA (ctDNA). In 2016 the first commercial ctDNA…

Competing interests A.R. is a founder, equity owner, and consultant at Halo Solutions and has served as a consultant at Tyra Biosciences. J.F.G. has served as a compensated consultant or received honoraria from Bristol Myers Squibb, Genentech/Roche, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, Moderna, Mirati, AstraZeneca, Pfizer, Novartis, iTeos, Nuvalent,…

PRESS RELEASE Published April 5, 2023 Epithelial Ovarian Cancer Drugs market research is a report that is the result of careful investigation into relevant and useful data. The data that was examined took into account both existing top players and potential new competitors. Epithelial Ovarian Cancer Drugs the leading companies’…

Mosaic Therapeutics, Ltd has closed its $28 million series A funding round. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital. The company also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO.  The Series A funding will be used to…

BIO-Europe Spring is one of Europe’s biggest biotech partnering events with discussion topics ranging from platform technologies and manufacturing to biotech investments. Here are some of the key take-home reports from the proceedings. The event, which took place from March 20 to 22, in the budding biotech hub of Basel,…

Preliminary results from a phase 3 trial demonstrated that Kisqali (ribociclib) plus endocrine therapy significantly reduced the risk for disease recurrence compared with endocrine therapy alone in patients with HR+/HER2- early breast cancer. These findings also showed that treatment with the CDK4/6 inhibitor Kisqali and endocrine therapy contributed to consistent…

David R. Liu, PhD, a professor at Harvard University, the Broad Institute of MIT and Harvard, and the Howard Hughes Medical Institute A research team led by gene editing pioneer David R. Liu, PhD, reports the application of base editing technology to develop a one-time treatment for spinal muscular atrophy…

North America Cold Sore Treatment (for HSV 1 Virus) Market analysis report covers detailed value chain analysis of the market. The value chain analysis helps to analyze major upstream raw materials, major equipment’s, manufacturing process, and downstream customer analysis and major distributor analysis are mentioned in the report along with…

SciePro – stock.adobe.com Ribociclib (Kisqali) from Novartis plus endocrine therapy met its primary endpoint of invasive disease-free survival in a broad population of individuals with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer and at risk of recurrence, according to positive topline results from a phase 3…

NEW YORK – Researchers from the Novartis Institutes for BioMedical Research (NIBR) have developed a method to determine clonal hematopoiesis in cancer patients from cell-free DNA (cfDNA) alone, using a computational model that can discriminate between blood-derived mutations arising from clonal hematopoiesis of indeterminate potential (CHIP) and tumor-derived mutations. CfDNA sequencing is gaining…

Pharming Group N.V. has announced that the US Food and Drug Administration (FDA) has approved Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.  Joenja, an oral, selective PI3Kδ inhibitor, is the first and only…

PRESS RELEASE Published March 27, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor T-Cell…

Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has announced a $123 million Series B financing. The financing was co-led by GordonMD Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management,…

Keratosis Pilaris Treatment Market Is Expected to rise at A CAGR Of 4.26% during the forecast period 2023 to 2031: Growth Plus Reports Newark, New Castle, USA, March 20, 2023 (GLOBE NEWSWIRE) — The global keratosis pilaris treatment market will register a revenue CAGR of 4.26%, owing to the high…

Data from 2 long-term studies demonstrated the sustained efficacy and durability of onasemnogene abeparvovec (Zolgensma) in children, a one-time gene therapy for the treatment of spinal muscular atrophy (SMA). The studies, LT-001 and LT-002, showed that the therapy had a favorable benefit-risk profile across a range of patient populations.1 The…

Introduction Case fatality rates of COVID-19 have decreased globally from 3·7% in March, 2020, to 1·0% in February, 2023, due in part to vaccination, changes in the prevailing SARS-CoV-2 variant, and improvements in clinical care. 1 Global case fatality rate from COVID-19 has decreased by 96·8% during 2·5 years of…

March 19, 2023 2 min read Source/Disclosures Published by: Source: Browning JC. Efficacy of berdazimer gel 10.3% in the treatment of molluscum contagiosum: Integrated results from the B-SIMPLE phase 3 program. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans. Disclosures: Browning reports being an investigator…

Introduction Though prevalence and mortality have been declining over the last 50 years, stomach cancer remains the fifth–most frequently diagnosed and fourth-leading cause of cancer-related death globally, accounting for over 1 million new cases and 769,000 deaths globally in 2020.1 Esophageal cancer follows closely behind, ranking seventh in terms of…

Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, has announced a $105 million financing. This includes a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures,…

PRESS RELEASE Published March 15, 2023 DelveInsight’s, “CAR-T Pipeline Insights 2023,” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in the CAR-T pipeline landscape. It covers the CAR-T pipeline drug profiles, including CAR-T clinical trial and nonclinical stage products. It also covers the CAR-T pipeline therapeutics assessment…

NEW YORK, March 15, 2023 /PRNewswire/ — Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2023-2027 Source: ReportLinker The analyst has been monitoring the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market and is forecast to grow by $ 2061.88 mn during 2022-2027, accelerating at a CAGR of 7.96% during the…

ADC Therapeutics SA 2022 Annual Report Table of Contents Letter to Shareholders Business Update Financial Review Corporate Governance Report from the Auditor on the Consolidated IFRS Financial Statements Consolidated IFRS Financial Statements for the Year Ended December 31, 2022 Report from the Auditor on the Statutory Financial Statements of ADC…

CE Activity Release Date: March 15, 2023CE Activity Expiration Date: February 28, 2024 Time to Complete activity: 1 hour ACTIVITY DESCRIPTION Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been…